Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2023 Filed Feb 21, 2023 23:13 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
Exercise / conversionOption (Right to Buy) · Derivative | 25,000 | $51.42 Strike: $51.42 | $1,285,500.00 |
DisclosureSEC source: 0001415889-23-002945 · form4-02212023_110202.xml · derivative · entry 11 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:13 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
SaleCommon Stock, $0.01 par value | 10,754 | $150.05 | $1,613,637.70 |
DisclosureSEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,208 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.71 to $150.05 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:13 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
SaleCommon Stock, $0.01 par value | 14,246 | $149.13 | $2,124,505.98 |
DisclosureSEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,962 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.69 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:13 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
Exercise / conversionCommon Stock, $0.01 par value | 25,000 | $51.42 | $1,285,500.00 |
DisclosureSEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:16 UTC |
AUSTIN ROXANNE SDirector
|
SaleCommon Stock, $0.01 par value | 10,000 | $150.50 | $1,505,000.00 |
DisclosureSEC source: 0001415889-23-002947 · form4-02212023_110231.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,705 Read SEC document |
| February 17, 2023 Filed May 9, 2023 21:01 UTC Amendment |
AUSTIN ROXANNE SDirector
|
SaleCommon Stock, $0.01 par value | 6,222 | $150.50 | $936,411.00 |
DisclosureSEC source: 0001415889-23-007667 · form4a-05092023_090506.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,483 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:59 UTC |
Michael Robert A.VICE CHAIRMAN
|
GrantOption (Right to Buy) · Derivative | 45,577 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002935 · form4-02212023_100213.xml · derivative · entry 5 Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,577 Underlying: Common Stock · 45,577 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,193 on February 16, 2024, 15,192 on February 16, 2025, and 15,192 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:59 UTC |
Michael Robert A.VICE CHAIRMAN
|
GrantCommon Stock, $0.01 par value | 10,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 4 Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,980 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:59 UTC |
Michael Robert A.VICE CHAIRMAN
|
GrantCommon Stock, $0.01 par value | 13,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,832 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:59 UTC |
Michael Robert A.VICE CHAIRMAN
|
GrantCommon Stock, $0.01 par value | 16,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,614 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:59 UTC |
Michael Robert A.VICE CHAIRMAN
|
GrantCommon Stock, $0.01 par value | 69,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,394 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
GrantOption (Right to buy) · Derivative | 21,944 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,944 Underlying: Common Stock · 21,944 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
GrantCommon stock, $0.01 par value | 7,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,089 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
GrantCommon stock, $0.01 par value | 8,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,709 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
GrantCommon stock, $0.01 par value | 11,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,149 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:00 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
GrantCommon stock, $0.01 par value | 51,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002936 · form4-02212023_110223.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,172 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:02 UTC |
Stewart Jeffrey RyanEVP, COMMERCIAL OPERATIONS
|
GrantOption (Right to Buy) · Derivative | 35,111 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002937 · form4-02212023_110234.xml · derivative · entry 6 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,111 Underlying: Common Stock · 35,111 shares Expires 2033-02-15 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,704 on February 16, 2024, 11,704 on February 16, 2025, and 11,703 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:02 UTC |
Stewart Jeffrey RyanEVP, COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 7,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002937 · form4-02212023_110234.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,166 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:02 UTC |
Stewart Jeffrey RyanEVP, COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 8,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002937 · form4-02212023_110234.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,324 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:02 UTC |
Stewart Jeffrey RyanEVP, COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 7,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002937 · form4-02212023_110234.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,512 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:02 UTC |
Stewart Jeffrey RyanEVP, COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 32,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002937 · form4-02212023_110234.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,026 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
GrantOption (Right to Buy) · Derivative | 114,787 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,787 Underlying: Common Stock · 114,787 shares Expires 2033-02-15 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,263 on February 16, 2024, 38,262 on February 16, 2025, and 38,262 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
GrantCommon Stock, $0.01 par value | 33,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,154 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
GrantCommon Stock, $0.01 par value | 39,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,944 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
GrantCommon Stock, $0.01 par value | 34,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,922 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
GrantCommon Stock, $0.01 par value | 149,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,985 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC |
Hudson Thomas JSVP, R&D AND CSO
|
GrantOption (Right to Buy) · Derivative | 20,256 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,256 Underlying: Common Stock · 20,256 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,752 on February 16, 2024, 6,752 on February 16, 2025, and 6,752 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC |
Hudson Thomas JSVP, R&D AND CSO
|
GrantCommon Stock, $0.01 par value | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,251 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC |
Hudson Thomas JSVP, R&D AND CSO
|
GrantCommon Stock, $0.01 par value | 7,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,901 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC |
Hudson Thomas JSVP, R&D AND CSO
|
GrantCommon Stock, $0.01 par value | 9,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,349 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC |
Hudson Thomas JSVP, R&D AND CSO
|
GrantCommon Stock, $0.01 par value | 40,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,868 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC |
Durkin Brian LVP, CONTROLLER
|
GrantOption (right to buy) · Derivative | 6,752 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · derivative · entry 5 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,752 Underlying: Common Stock · 6,752 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,251 on February 16, 2024, 2,251 on February 16, 2025, and 2,251 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC |
Durkin Brian LVP, CONTROLLER
|
GrantCommon Stock, $0.01 par value | 2,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,331 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC |
Durkin Brian LVP, CONTROLLER
|
GrantCommon Stock, $0.01 par value | 3,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,025 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC |
Durkin Brian LVP, CONTROLLER
|
GrantCommon Stock, $0.01 par value | 3,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,879 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC |
Durkin Brian LVP, CONTROLLER
|
GrantCommon Stock, $0.01 par value | 16,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,136 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
GrantOption (Right to buy) · Derivative | 33,760 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002942 · form4-02212023_110227.xml · derivative · entry 5 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,760 Underlying: Common Stock · 33,760 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,254 on February 16, 2024, 11,253 on February 16, 2025, and 11,253 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
GrantCommon Stock, $0.01 par value | 2,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002942 · form4-02212023_110227.xml · nonDerivative · entry 4 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,434 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
GrantCommon Stock, $0.01 par value | 3,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002942 · form4-02212023_110227.xml · nonDerivative · entry 3 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,036 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
GrantCommon Stock, $0.01 par value | 4,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002942 · form4-02212023_110227.xml · nonDerivative · entry 2 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,890 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:10 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
GrantCommon Stock, $0.01 par value | 18,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002942 · form4-02212023_110227.xml · nonDerivative · entry 1 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,524 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
GrantOption (Right to buy) · Derivative | 21,944 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,944 Underlying: Common Stock · 21,944 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
GrantCommon Stock, $0.01 par value | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,168 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
GrantCommon Stock, $0.01 par value | 2,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,322 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
GrantCommon Stock, $0.01 par value | 3,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,182 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
GrantCommon Stock, $0.01 par value | 14,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,814 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
GrantOption (Right to Buy) · Derivative | 13,166 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · derivative · entry 8 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,166 Underlying: Common Stock · 13,166 shares Expires 2033-02-15 F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,389 on February 16, 2024, 4,389 on February 16, 2025, and 4,388 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 3,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,679 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 4,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,805 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
GrantCommon Stock, $0.01 par value | 6,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,147 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.